Liminatus Pharma Inc(LIMN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -21.48 | Insider Own | 41.73% | Shs Outstand | 1.1M | Perf Week | 21.02% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.8M | Perf Month | -13.7% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 1.41% | Short Float | 12.24% | Perf Quarter | -21.82% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.14 | Perf Half Y | -60.16% |
| Sales | 0.00B | P/B | 15.01 | EPS next 5Y | - | ROA | -471.47% | Short Interest | 0.10M | Perf YTD | -86.79% |
| Book/sh | 0.27 | P/C | 1.79 | EPS past 3/5Y | - -540.05% | ROE | - | 52W High | -97.15% ($141.50) | Perf Year | -95.2% |
| Cash/sh | 2.25 | P/FCF | - | Sales past 3/5Y | - | ROIC | -4165.92% | 52W Low | 22.49% ($3.29) | Perf 3Y | -99.24% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -107.04% | Gross Margin | - | Volatility(W/M) | 7.64% 8.22% | Perf 5Y | -99.17% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.44 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.12 | EPS Q/Q | -698.35% | Profit Margin | - | RSI (14) | 47.5 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.12 | Sales Q/Q | - | SMA20 | 7.52% ($3.75) | Beta | 0.76 | Target Price | - |
| Payout | - | Debt/Eq | 4.8 | Earnings | - | SMA50 | -18.39% ($4.94) | Rel Volume | 0.03 | Prev Close | $4.07 |
| Employees | 1 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -74.48% ($15.79) | Avg Volume(3M) | 0.67M | Price | $4.03 |
| IPO | 2021/5/26 | Option/Short | No/Yes | Trades | 315 | Volume | 17,701 | Change | -0.98% |
Company
LIMN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Lymminatus Pharma () is a clinical- and preclinical-stage biopharma company specializing in targeted immuno-oncology, with its core pipeline consisting of a GCC (Guanylyl Cyclase C) vaccine candidate for GCC-expressing gastrointestinal cancers and IBA101, a next-generation CD47-blocking antibody for solid tumors. The company went public on Nasdaq through a SPAC merger and is currently restructuring its capital structure, most recently signing a $30 million equity financing MOU with Capital Trust Group.
Over the past 1 year, on the lower side
97% below its 1-year high.
LIMN has weak earning power
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Holding long would have lost money
Would have changed by -99.2% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership is about average
Institutions hold 1.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
VXF 0.00%It ranks #4 in the industry
Based on market cap of $5M.
LIMN $5M PER -
VRTX $131B PER 30.0
REGN $83B PER 19.8
MRNA $73B PER -
FAQ
What kind of company is LIMN?
LIMN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LIMN?
The market cap of LIMN is approximately $5M, ranking 5,672 within its sector.
What is the 52-week high and low for LIMN?
LIMN has recorded a 52-week high of $141.50 and a low of $3.29.
